Skip to main content
SpringerLink
Log in

Polypharmazie in der Behandlung von Angst- und Zwangsstörungen

  • Chapter
Polypharmazie in der Behandlung psychischer Erkrankungen

  • 324 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

4. Literatur

  1. Agid O, Lerer B (1999) Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology. J Clin Psychiaty 60: 55–56

    CAS  Google Scholar 

  2. D’Amico G, Cedro C, Muscatello MR, Pandolfo G, Di Rosa AE, Zoccali R, La Torre D, D’Arrigo C, Spina E (2003) Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 27: 619–623

    Article  CAS  Google Scholar 

  3. Atmaca M, Kuloglu M, Tezcan E, Gecici O (2002) Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 17: 115–119

    Article  PubMed  CAS  Google Scholar 

  4. Bandelow B, Rüther E (2004) Treatment-resistant panic disorder. CNS Spectrums 9: 725–739

    PubMed  Google Scholar 

  5. Bartzokis G, Freeman T, Roca V, Kimbrell T, Brown SJ, Lu PH, Turner J, Mintz J, Saunders S (2003) Risperidone in the treatment of chronic combat-related posttraumatic stress disorder [abstract]. Biol Psychiatry 53: 135S

    Article  Google Scholar 

  6. Baxter LR, Li X, Jackson WT, May RS, Tolbert LC (2002) Adjunctive risperidone in the treatment of SSRI-refractory obsessive-compulsive disorder. Presented at the Society of Biological Psychiatry Annual Meeting, Philadelphia

    Google Scholar 

  7. Blier P (2001) Possible neurobiological mechanisms underlying faster onset of antidepressant action. J Clin Psychiatry 62[Suppl] 4: 7–11

    PubMed  CAS  Google Scholar 

  8. Blier P, Bergeron R (1996) Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings. Int Clin Psychopharmacol 11: 37–44

    PubMed  CAS  Google Scholar 

  9. Bogan AM, Koran LM, Chuong HW, Vapnik T, Bystritsky A (2005) Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study. J Clin Psychiatry 66: 73–79

    PubMed  CAS  Google Scholar 

  10. Bogetto F, Bellino S, Vaschetto P, Ziero S (2000) Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res 96: 91–98

    Article  PubMed  CAS  Google Scholar 

  11. Brawman-Mintzer O, Knapp R, Nietert P (2004) Risperidone augmentation in treatment-resistant Generalized Anxiety Disorder. Presented at the 24th Annual Conference of the Anxiety Disorder Association of America (ADAA), Miami, Florida

    Google Scholar 

  12. Bystritsky A, Ackerman A, Rosen RM, Vapnik T, Gorbis E, Maidmant KM, Saxena S (2001) Augmentation of SSRI response in refractory OCD using adjunctive olanzapine: a placebo-controlled trial. Presented at the 5th International Obsessive-Compulsive Disorders Conference, Sardinia, Italy

    Google Scholar 

  13. Chao IL (2004) Olanzapine augmentation in panic disorder [Letter]. Pharmacopsychiatry 37: 239–240

    Article  PubMed  CAS  Google Scholar 

  14. Cohen LS (2003) Quetiapine in treatment resistant obsessive-compulsive disorder [letter]. J Am Acad Child Adolesc Psychiatry 42: 623–624

    Article  PubMed  Google Scholar 

  15. Cora-Locatelli G, Greenberg BD, Martin J, Murphy D (1998) Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder [letter]. J Clin Psychiatry 59[Suppl] 9: 480–481

    PubMed  CAS  Google Scholar 

  16. Crockett BA, Churchilli E, Davidson JRT (2004) A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder. Ann Clin Psychiatry 16: 127–132

    PubMed  Google Scholar 

  17. Dannon PN, Iancu I, Grunhaus LJ (1999) Short-term potentiation of paroxetine with clonazepam in the treatment of patients with panic disorder [abstract, pp 153]. APA, Washington, D.C.

    Google Scholar 

  18. Dannon PN, Sasson Y, Hirschmann S, Iancu I, Grunhaus LJ, Zohar J (2000) Pindolol augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol 10: 165–169

    Article  PubMed  CAS  Google Scholar 

  19. David D, DeFaria L, Lapeyra O, Mellan TA (2002) Adjunctive risperidone in chronic combat-related posttraumatic stress disorder [abstract]. Int J Neuropsychopharmacol 5[Suppl] 1: 130

    Google Scholar 

  20. Delgado PL, Goodman WK, Price LH, Heninger GR, Charney DS (1990) Fluvoxamine/pimozide treatment of concurrent Tourette’s and obsessive-compulsive disorder. Br J Psychiatry 157: 762–765

    Article  PubMed  CAS  Google Scholar 

  21. Denys D, van Megen H, Westenberg H (2002) Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder. An open-label study. J Clin Psychiatry 63: 700–703

    PubMed  CAS  Google Scholar 

  22. Denys D, de Gues F, van Mengen HJGM, Westenberg HGM (2004) A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 65: 1040–1048

    PubMed  CAS  Google Scholar 

  23. Eppel AB (1989) Imipramine and clonazepam for panic disorder. Am J Psychiatry 146: 283

    PubMed  CAS  Google Scholar 

  24. Erzegovesi S, Gulielmo E, Siliprandi F, Bellodi L (2005) Low-dose risperidone augmentation of fluvoxamine treatment in obesessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol 15: 69–74

    Article  PubMed  CAS  Google Scholar 

  25. Etxebeste M, Aragüés E, Malo P, Pacheco L (2000) Olanzapine and panic attacks. Am J Psychiatry 157: 659–660

    Article  PubMed  CAS  Google Scholar 

  26. Figueroa Y, Rosenberg DR, Birmaher B, Keshavan MS (1998) Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents. J Child Adolesc Psychopharmacol 8: 61–67

    PubMed  CAS  Google Scholar 

  27. Filteau MJ, Leblanc J, Bouchard RH (2003) Quetiapine reduces flashbacks in chronic posttraumatic stress disorder [letter]. Can J Psychiatry 48: 282–283

    PubMed  Google Scholar 

  28. Fitzgerald KD, Stewart CM, Tawille V, Rosenberg DR (1999) Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. J Child Adolesc Psychopharmacol 9: 115–123

    PubMed  CAS  Google Scholar 

  29. Francobandiera G (2001) Olanzapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder: an open study. Can J Psychiatry 46: 356–358

    PubMed  CAS  Google Scholar 

  30. Fux M, Benjamin J, Belmaker RH (1999) Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: A double-blind cross-over study. In J Neuropsychopharmacol 2: 193–195

    Article  CAS  Google Scholar 

  31. Gastfriend D, Rosenbaum J (1989) Adjunctive buspirone in benzodiazepine treatment of four patients with panic disorder. Am J Psychiatry 146: 914–916

    PubMed  CAS  Google Scholar 

  32. Goddard AW, Brouette T, Almai A, Jetty P, Ciary C, Woods S, Charney D (2001) Early co-administration of clonazepam with sertralin: a safe, rapidly acting treatment for panic disorder. Arch Gen Psychiatry 58: 681–686

    Article  PubMed  CAS  Google Scholar 

  33. Goldstein S (1986) Sequential treatment of panic disorder with alprazolam and imipramine. Am J Psychiatry 143: 1634

    PubMed  CAS  Google Scholar 

  34. Grady T, Pigott TA, L’Heureux F, Hill J, Bernstein L, Murphy D (1993) A double-blind study of adjuvant buspirone hydrochloride in fluoxetine-treated patients with OCD. Am J Psychiatry 150: 819–821

    PubMed  CAS  Google Scholar 

  35. Hamner MB, Deitsch SE, Brodrick PS, Ulmer HG, Lorberbaum JP (2002) Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol 23: 15–20

    Article  Google Scholar 

  36. Hamner MB, Faldowski RA, Ulmer HG, Frueh BC, Huber MG, Arana GW (2003) Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol 18: 1–8

    Article  PubMed  CAS  Google Scholar 

  37. Hirschmann S, Dannon PN, Iancu I, Dolberg OT, Zohar J, Grunhaus L (2000) Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 20: 556–559

    Article  PubMed  CAS  Google Scholar 

  38. Hollander E, Baldini Ross N, Sood E, Pallanti S (2003) Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol 6: 397–401

    Article  PubMed  CAS  Google Scholar 

  39. Iwata Y, Kotani Y, Hoshino R, Takei N, Iyo M, Mori N (2000) Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder [letter]. J Clin Psychiatry 61: 528–529

    PubMed  CAS  Google Scholar 

  40. Jakovljević M, Šagud M, Mihaljević-Pelesš A (2003) Olanzapine in the treatment-resistant combat-related PTSD — a series of case reports. Acta Psychiatr Sand 107: 394–396

    Article  Google Scholar 

  41. Jenike MA, Baer L, Buttolph L (1991) Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder. J Clin Psychiatry 1: 13–14

    Google Scholar 

  42. Kasper S (2003) Neurotische, Belastungs-und Somatoforme Störungen. In: Kasper S, Volz HP (Hrsg) Psychiatrie compact. Thieme, Stuttgart, S 133–168

    Google Scholar 

  43. Keck PE Jr, McElroy SL, Tugrul KC, Bennett JA, Smith HM (1993) Antiepileptic drugs for the treatment of panic disorder. Neuropsychobiology 27: 150–153

    Article  PubMed  Google Scholar 

  44. Khaldi S, Kornreich C, Dan B, Pelc I (2003) Usefulness of olanzapine in refractory panic patients. J Clin Psychopharmacol 23: 100–101

    Article  PubMed  Google Scholar 

  45. Koran LM, Ringold AL, Elliot MA (2000) Olanzapine augmentation for treatmentresistant obsessive-compulsive disorder. J Clin Psychiatry 61[Suppl] 7: 514–517

    PubMed  CAS  Google Scholar 

  46. Leonard HL, Topol D, Burkstein O, Hindmarsh D, Allen AJ, Swedo SE (1994) Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 33: 792–794

    PubMed  CAS  Google Scholar 

  47. Lykouras L, Alevizos B, Michalopoulou P, Rabavilas A (2003) Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of reported cases. Progr Neuro-Psychopharmacol Biol Psychiatry 27: 333–346

    Article  Google Scholar 

  48. Maina G, Albert U, Ziero S, Bogetto F (2003) Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued? Int Clin Psychopharmacol 18: 23–28

    Article  PubMed  Google Scholar 

  49. Mancini C, Van Ameringen M, Farvolden P (2002) Does SSRI augmentation with antidepressants that influence noradrenergic function resolve depression in obsessive-compulsive disorder? J Affect Dis 68: 59–65

    Article  PubMed  CAS  Google Scholar 

  50. Marazitti D, Pallanti S (1999) Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. Am J Psychiatry 156: 1834–1835

    Google Scholar 

  51. Markovitz PJ, Stagno SJ, Calabrese JR (1990) Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry 147: 798–800

    PubMed  CAS  Google Scholar 

  52. Mattes JA (1986) A pilot study of combined trazodone and tryptophan in obsessive-compulsive disorder. Int Clin Psychopharmacol 1: 170–173

    PubMed  CAS  Google Scholar 

  53. McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, Heninger GR (1990) Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 147: 652–654

    PubMed  CAS  Google Scholar 

  54. McDougle C, Price L, Goodman W, Charney D, Heninger G (1991) A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder. J Clin Psychopharmacol 11: 175–184

    PubMed  CAS  Google Scholar 

  55. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH (1994) Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 51: 302–308

    PubMed  CAS  Google Scholar 

  56. McDougle CJ, Fleischmann RL, Epperson CN, Wasylink S, Leckman JF, Price LH (1995) Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry 56: 527–528

    Google Scholar 

  57. McDougle CJ, Eppersen CN, Pelton GH, Wasylink S, Price LH (2000) A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitory-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 57: 794–801

    Article  PubMed  CAS  Google Scholar 

  58. Misri S, Milis L (2004) Obsessive-compulsive disorder in the postpartum. Open-label trial of quetiapine augmentation. J Clin Psychopharmacol 24: 624–627

    Article  PubMed  CAS  Google Scholar 

  59. Mohr N, Vythilingum B, Ernsley RA, Stein DJ (2002) Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int Clin Psychopharmacol 17: 37–40

    Article  PubMed  CAS  Google Scholar 

  60. Monnelly E, Ciraulo DA, Knapp CM, Keane TM (2002) Low dose adjunctive risperidone in combination treatment of irritable aggression in PTSD. 40th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Waikoloa, Hawaii, p 349

    Google Scholar 

  61. Mundo E, Guglielmo E, Bellodi L (1998) Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int J Psychopharmacol 13: 219–224

    Article  CAS  Google Scholar 

  62. Noorbala AA; Hosseini SH, Mohammadi MR, Akhondzadeh S (1998) Combination of clomipramine in the treatment of obsessive-compulsive disorder: a double-blind, placebo-controlled trial. J Clin Pharm Ther 23: 155–159

    Article  PubMed  CAS  Google Scholar 

  63. Ontiveros A, Fontaine R (1992) Sodium valproate and clonazepam for treatment-resistant panic disorder. J Psychiatry Neurosci 17: 78–80

    PubMed  CAS  Google Scholar 

  64. Oshimo T, Ohta M, Ueno R, Hashimoto T, Shirakawa O, Maeda K (2003) Effects of combined use of serotonin reuptake inhibitor and risperidone for obsessive-compulsive disorders [abstract]. Int Clin Psychopharmacol 18: 185

    Article  Google Scholar 

  65. Pallanti S, Quercioli L, Paiva RS, Koran LM (1999) Citalopram for treatment-resistant obsessive-compulsive disorder. Eur Psychiatry 14: 101–106

    Article  PubMed  CAS  Google Scholar 

  66. Pallanti S, Quercioli L, Bruscoli M (2004) Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry 65: 1394–1399

    Article  PubMed  CAS  Google Scholar 

  67. Pfanner C, Marazziti D, Dell’Osso L, Presta S, Gemignani A, Milanfranchi A, Cassano GB (2000) Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. Int Clin Psychopharmacol 15: 297–301

    Article  PubMed  CAS  Google Scholar 

  68. Pigott TA, L’Heureux F, Hill JL, Bihari K, Bernstein SE, Murphy DL (1992) A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 12: 11–18

    CAS  Google Scholar 

  69. Pollack MH, Simon NM, Worthington JJ, Doyle AL, Peters P, Toshkov F, Otto MW (2003) Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol 17: 276–282

    Article  PubMed  CAS  Google Scholar 

  70. Rasmussen S (1984) Lithium and tryptophan augmentation in clomipramine-resistant OCD. Am J Psychiatry 141: 1283–1285

    PubMed  CAS  Google Scholar 

  71. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G (1996) Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol Bull 32: 677–682

    PubMed  CAS  Google Scholar 

  72. Riddle MA, Leckman JF, Hardin MT, Anderson GM, Cohen DJ (1988) Fluoxetine treatment of obsessions and compulsions in patients with Tourette’s syndrome [letter]. Am J Psychiatry 145: 1173–1174

    PubMed  CAS  Google Scholar 

  73. Sareen J, Kirshner A, Lander M, Kjernisted KD, Eleff MK, Reiss JP (2004) Do antipsychotics ameliorate or exacerbate obsessive-compulsive disorder symptoms? A systematic review. J Affect Disord 82: 167–174

    Article  PubMed  CAS  Google Scholar 

  74. Sattar SP, Ucci B, Grant K, Bhatia SC, Petty F (2002) Quetiapine therapy for posttraumatic stress disorder. Ann Pharmacother 36: 1875–1878

    Article  PubMed  Google Scholar 

  75. Saxena S, Wang D, Bystritsky A, Baxter LR (1996) Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 57: 303–306

    PubMed  CAS  Google Scholar 

  76. Seedat S, Stein MB (2004) Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry 65: 244–248

    PubMed  CAS  Google Scholar 

  77. Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MCK, Blier P, Goodman WK (2004) A double-blind, placebo-controlled trial of olanzapine addition to fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry 55: 553–555

    Article  PubMed  CAS  Google Scholar 

  78. Simon NM, Safren SA, Otto MW, Sharma SG, Lanka GD, Pollack MH (2002) Longitudinal outcome with pharmacotherapy in a naturalistic study of panic disorders. J Affect Dis 69: 33–34

    Google Scholar 

  79. States JH, St. Dennis CK (2003) Chronic sleep disruption and the reexperiencing cluster of posttraumatic stress disorder symptoms are improved by olanzapine: Brief review of the literature and a case-based series. J Clin Psychiatry 5: 74–79

    Google Scholar 

  80. Stein MB, Kline NA, Matloff JL (2002) Adjunctive olanzapine for SSRI-resistant combat-related PTSD: A double-blind, placebo-controlled study. Am J Psychiatry 159: 1777–1779

    Article  PubMed  Google Scholar 

  81. Tiffon L, Coplan JJD, Papp LA, Gorman JM (1994) Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. J Clin Psychiatry 55: 66–69

    PubMed  CAS  Google Scholar 

  82. Uhlenhuth EH, Balter MB, Ban TA, Yang K (1998) International study of expert judgement on therapeutic use of benzodiazepines and other psychotherapeutic medications: V. Treatment strategies in panic disorder, 1992–1997. J Clin Psychopharmacol 18[Suppl] 2: 27–31

    Article  Google Scholar 

  83. Van Ameringen M, Mancini C, Wilson C (1996) Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord 39: 115–121

    Article  PubMed  Google Scholar 

  84. Weiss EL, Potenza MN, McDougle CJ, Epperson CN (1999) Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry 60: 524–527

    PubMed  CAS  Google Scholar 

  85. Woods SW, Nagy LM, Koleszar AS, Krystal JH, Heninger GR, Charney DS (1992) Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder. J Clin Psychopharmacol 12: 32–38

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Krankenhaus für Psychiatrie, Psychotherapie und Psychosomatische Medizin, Schloß Werneck, Balthasar-Neumann-Platz 1, 97440, Werneck

    Prof. Dr. med. Hans -Peter Volz

Authors
  1. Prof. Dr. med. Hans -Peter Volz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag/Wien

About this chapter

Cite this chapter

Volz, H.P. (2006). Polypharmazie in der Behandlung von Angst- und Zwangsstörungen. In: Polypharmazie in der Behandlung psychischer Erkrankungen. Springer, Vienna. https://doi.org/10.1007/3-211-31221-8_8

Download citation

  • DOI: https://doi.org/10.1007/3-211-31221-8_8

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-25286-4

  • Online ISBN: 978-3-211-31221-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation